IS5953A - Lyfjablöndur úr örgerðum eplerenonum - Google Patents

Lyfjablöndur úr örgerðum eplerenonum

Info

Publication number
IS5953A
IS5953A IS5953A IS5953A IS5953A IS 5953 A IS5953 A IS 5953A IS 5953 A IS5953 A IS 5953A IS 5953 A IS5953 A IS 5953A IS 5953 A IS5953 A IS 5953A
Authority
IS
Iceland
Prior art keywords
eplerenones
microplated
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
IS5953A
Other languages
English (en)
Other versions
IS2325B (is
Inventor
S. Thosar Shilpa
D. Gokhale Rajeev
S. Tolbert Dwain
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5953(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Publication of IS5953A publication Critical patent/IS5953A/is
Publication of IS2325B publication Critical patent/IS2325B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5953A 1998-12-09 2001-05-25 Örgerðar samsetningar epleróns IS2325B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11164698P 1998-12-09 1998-12-09
PCT/US1999/029136 WO2000033847A1 (en) 1998-12-09 1999-12-08 Micronized eplerenone compositions

Publications (2)

Publication Number Publication Date
IS5953A true IS5953A (is) 2001-05-25
IS2325B IS2325B (is) 2007-12-15

Family

ID=22339668

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5953A IS2325B (is) 1998-12-09 2001-05-25 Örgerðar samsetningar epleróns

Country Status (30)

Country Link
US (7) US6410054B1 (is)
EP (1) EP1135139B1 (is)
JP (1) JP2002531508A (is)
KR (1) KR100671275B1 (is)
CN (1) CN1230179C (is)
AR (1) AR028982A1 (is)
AT (1) ATE249223T1 (is)
AU (1) AU763166B2 (is)
BR (1) BR9915964A (is)
CA (1) CA2326842A1 (is)
CZ (1) CZ20011942A3 (is)
DE (1) DE69911240T2 (is)
DK (1) DK1135139T3 (is)
EA (1) EA003266B1 (is)
ES (1) ES2207977T3 (is)
HK (1) HK1041641B (is)
HU (1) HU224428B1 (is)
ID (1) ID30115A (is)
IL (1) IL143301A0 (is)
IS (1) IS2325B (is)
MY (1) MY125651A (is)
NO (1) NO20012782L (is)
NZ (1) NZ511869A (is)
PL (1) PL198425B1 (is)
PT (1) PT1135139E (is)
TR (1) TR200101643T2 (is)
TW (1) TWI234459B (is)
UA (1) UA74141C2 (is)
WO (1) WO2000033847A1 (is)
ZA (1) ZA200104361B (is)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
JP2004511435A (ja) * 2000-07-27 2004-04-15 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とβ−アドレナリン作動性拮抗薬の併用療法
AU2001280804A1 (en) * 2000-07-27 2002-02-13 Eileen R. Blasi Aldosterone blocker therapy to prevent or treat inflammation-related disorders
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
CN1537019A (zh) * 2001-07-19 2004-10-13 �ź㴫 醛固酮受体拮抗剂和HMG CoA还原酶抑制剂的药物组合
MXPA04005803A (es) * 2001-12-13 2004-11-01 Pharmacia Corp Metodos para tratamiento o profilaxis de efectos patogenicos mediados por aldosterona en un sujeto utilizando un antagonista de aldosterona epoxi-esteroidal.
EP1469884A1 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
MY135609A (en) * 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003225871A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
WO2003090755A1 (en) * 2002-04-26 2003-11-06 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
MXPA05002062A (es) * 2002-08-23 2005-06-08 Pharmacia Corp Modulacion de la actividad de la metaloproteinasa de la matriz con bloqueador(es) de aldosterona.
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
EP1620107A1 (en) * 2003-04-25 2006-02-01 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
AU2004249211A1 (en) * 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
US7198653B2 (en) * 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
EP1663182B2 (en) * 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US7846466B2 (en) * 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
CA2585003C (en) * 2004-11-23 2010-08-17 Dong Wha Pharm. Ind. Co., Ltd. An oral preparation having improved bioavailability
WO2006097342A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process for making steroidal compounds
US20060252738A1 (en) * 2005-05-06 2006-11-09 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
US20060275356A1 (en) * 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US20070095705A1 (en) * 2005-10-31 2007-05-03 Legault Dennis X Array of packages
CA2965211C (en) * 2006-01-13 2020-06-30 Indiana University Research & Technology Corporation Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
PL2037887T3 (pl) * 2006-05-31 2011-03-31 Vertex Pharma Doustne preparaty o kontrolowanym uwalnianiu inhibitora enzymu konwertującego interleukinę 1 beta
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP2124959A4 (en) * 2006-12-21 2011-09-14 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION
WO2008089549A1 (en) 2007-01-22 2008-07-31 Genpharm Ulc Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
JP5284967B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 打錠障害を生じない錠剤製剤
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20090232896A1 (en) * 2008-03-11 2009-09-17 Mallinckrodt Inc. Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions
US8343524B2 (en) * 2008-07-31 2013-01-01 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
MX2012001973A (es) * 2009-08-28 2012-04-11 Hercules Inc Composicion de revestimiento de pelicula de compuestos de polvo solidos.
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
EA201290556A1 (ru) * 2009-12-23 2013-01-30 Рациофарм Гмбх Оральная лекарственная форма, включающая энтекавир
EA026094B1 (ru) 2009-12-23 2017-03-31 Рациофарм Гмбх Твердая лекарственная форма тикагрелора
WO2011158870A1 (ja) * 2010-06-16 2011-12-22 帝人ファーマ株式会社 放出制御型の有核錠剤
TR201007653A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
KR20120093461A (ko) * 2011-01-27 2012-08-23 양지화학 주식회사 정제형 감미료 조성물 및 그 제조방법
WO2013095311A1 (en) 2011-11-25 2013-06-27 Mahmut Bilgic Inhalation device
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
FR3001890B1 (fr) * 2013-02-08 2015-08-07 Greenpharma Sas Composition dermatologique pour repousse des poils ou des cheveux
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US11007203B2 (en) * 2013-10-06 2021-05-18 Salim Shah Formulations comprising aldosterone receptor antagonists and treatments using same
EP3079697B1 (en) 2013-12-12 2021-02-03 Cornell University Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
FR3019045A1 (fr) * 2014-03-26 2015-10-02 Greenpharma Sas Composition dermatologique pour la repousse des poils ou des cheveux
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
WO2016063269A1 (en) 2014-10-20 2016-04-28 Prendergast Patrick T Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae
JP2018504454A (ja) 2015-01-12 2018-02-15 ナノ ファーマシューティカル ラボラトリーズ エルエルシーＮａｎｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌａｂｏｒａｔｏｒｉｅｓ ＬＬＣ 積層徐放型マイクロビーズ及びその作製方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
GB201913972D0 (en) * 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082751A (en) * 1976-02-13 1978-04-04 Bristol-Myers Company Therapeutic agents
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4753802A (en) 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4847093A (en) 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
NZ238867A (en) 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
WO1992013547A1 (en) 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
GB9311191D0 (en) 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
WO1998025949A1 (en) 1996-12-09 1998-06-18 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
PT944644E (pt) 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon

Also Published As

Publication number Publication date
KR20010101132A (ko) 2001-11-14
CZ20011942A3 (cs) 2001-12-12
HK1041641B (zh) 2006-04-28
AR028982A1 (es) 2003-06-04
US6410054B1 (en) 2002-06-25
DE69911240T2 (de) 2004-07-15
CN1230179C (zh) 2005-12-07
NZ511869A (en) 2003-05-30
ES2207977T3 (es) 2004-06-01
BR9915964A (pt) 2001-08-28
AU1936800A (en) 2000-06-26
PT1135139E (pt) 2004-02-27
EP1135139B1 (en) 2003-09-10
TWI234459B (en) 2005-06-21
CN1329494A (zh) 2002-01-02
HU224428B1 (hu) 2005-09-28
US7157101B2 (en) 2007-01-02
WO2000033847A1 (en) 2000-06-15
US20040192661A1 (en) 2004-09-30
US20030215518A1 (en) 2003-11-20
US6863902B2 (en) 2005-03-08
ID30115A (id) 2001-11-08
US6495165B1 (en) 2002-12-17
EP1135139A1 (en) 2001-09-26
HUP0104718A3 (en) 2002-10-28
US6558707B1 (en) 2003-05-06
CA2326842A1 (en) 2000-06-15
AU763166B2 (en) 2003-07-17
US20030072808A1 (en) 2003-04-17
IL143301A0 (en) 2002-04-21
DK1135139T3 (da) 2004-01-05
HK1041641A1 (en) 2002-07-19
US20020136775A1 (en) 2002-09-26
HUP0104718A2 (hu) 2003-01-01
JP2002531508A (ja) 2002-09-24
NO20012782L (no) 2001-07-03
IS2325B (is) 2007-12-15
KR100671275B1 (ko) 2007-01-19
ATE249223T1 (de) 2003-09-15
PL198425B1 (pl) 2008-06-30
EA200100519A1 (ru) 2002-02-28
EA003266B1 (ru) 2003-02-27
ZA200104361B (en) 2002-05-28
TR200101643T2 (tr) 2002-04-22
US6534093B1 (en) 2003-03-18
NO20012782D0 (no) 2001-06-06
UA74141C2 (uk) 2005-11-15
DE69911240D1 (de) 2003-10-16
MY125651A (en) 2006-08-30
US6592902B2 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
ID23299A (id) Formulasi-formulasi farmasi
IS6040A (is) Valdekoxib efnablöndur
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
NO20020304L (no) Konserverte farmasoytiske preparater
NO20005218D0 (no) Farmasøytisk aerosolpreparat
NO20001776L (no) Medikamenter
NO20071303L (no) Farmasoytiske preparater
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
ID24654A (id) Formulasi farmasi omeprazola
ID29089A (id) Sediaan farmasi moksifloksasin
NO980546D0 (no) Farmasöytiske midler
DK1466615T3 (da) Farmaceutisk præparat
ID27150A (id) Sediaan levotiroksin bahan farmasi
DE69926012D1 (de) Arzneizubereitungen
ID16781A (id) Formulasi-formulasi farmasi
NO994619L (no) Farmasöytiske blandinger
ATE246494T1 (de) Brausezubereitungen
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
DE69906934D1 (de) Arzneizubereitungen
NO20016430L (no) Farmasöytisk kompleks
EP1142589A4 (en) Medicinal preparations
DE50009295D1 (de) Vernetzerfreie zubereitungen
NO994436L (no) Farmasöytiske sammensetninger
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste